Thyroid gland metastasis from breast cancer: A rare case report and literature overview

Introduction. The thyroid gland is a rare site for metastatic lesions from non-thyroid cancers. Due to the fact that achieving a diagnosis of thyroid gland metastasis from breast cancer prior to operation is challenging, the diagnosis thereof is mainly based on a pathological biopsy and immunohistochemical staining. The aim of this study was to present a rare case of thyroid gland metastasis from lobular breast cancer. Case outline. The patient was a 33-year-old female who had already had a five-year history of lobular cancer of the right breast and was thereafter found to have two suspicious tumors in the left breast, as well as a thyroid mass diagnosed as metastatic breast carcinoma. Conclusion. Patients who have a thyroid lesion and a history of malignancy are at a higher risk for metastasis and require additional caution during diagnosis and treatment.

Download Full-text

Excision of metastatic breast cancer from sternum and reconstruction in two patients with solitary metastatic spread

Journal of Surgical Case Reports ◽

10.1093/jscr/rjaa272 ◽

2020 ◽

Vol 2020 (8) ◽

Author(s):

Saifullah Mohamed ◽

Khurum Mazhar ◽

Ahmed Osman ◽

Akshay Patel ◽

Lakshmi Srinivasan ◽

...

Keyword(s):

Breast Cancer ◽

Breast Carcinoma ◽

Previous History ◽

Metastatic Breast ◽

Extent Of Resection ◽

Left Breast ◽

Term Survival ◽

Metastatic Breast Carcinoma ◽

History Of ◽

Treated Breast

Abstract Metastatic breast carcinoma is a relatively common clinical entity. However, the prognosis of oligometastatic and polygometastatic disease differs considerably pertaining to five-year survival. Metastatic breast carcinoma to the sternum has been described as early as 1988. We describe two cases in our institution who presented with solitary sternal metastases with a previous history of treated breast cancer. In both cases, there had been a history of previous left breast cancer treated aggressively with surgical resection and adjuvant oncological therapy and maintenance hormonal therapy. Partial sternectomy or total sternectomy for solitary metastatic sternal deposits is well established with relatively low morbidity and mortality and improvement in quality of life and possible improvement in long-term survival. Furthermore, reconstructive options are inherently dependent on extent of resection performed. These techniques can incorporate the use of sternal plates in order to approximate defects and reinforce the sternum in the setting of partial sternectomy.

Download Full-text

Effectiveness of combination with eribulin in third line of chemotherapy for triple negative breast cancer (case report)

Medical alphabet ◽

10.33667/2078-5631-2021-31-20-24 ◽

2021 ◽

Vol 1 (31) ◽

pp. 20-24

Author(s):

M. V. Kalugin ◽

K. A. Ivanova ◽

E. I. Borisova ◽

S. S. Nakhapetyan ◽

S. L. Gutorov

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Breast Cancer Case ◽

Cancer Case ◽

Antitumor Action ◽

Illustrative Case ◽

Development Of Resistance ◽

Triple Negative Phenotype

In most cases triple negative breast cancer is characterized by an aggressive course of disease and early development of resistance to chemotherapy. Thereafter, the late-line treatment choice, usually after anthracyclines and taxanes, is problematic due to the limited amount of effective and low-toxic cytostatics. In our opinion, in this situation the use of eribulin which possesses unique antitumor action mechanisms is a good option. An illustrative case of a pronounced antitumor effect of eribulin in metastatic breast cancer with triple negative phenotype resistant to previous lines of chemotherapy is presented.

Download Full-text

Experience with eribulin in triple-negative metastatic breast cancer: case studies

Future Oncology ◽

10.2217/fon-2017-0356 ◽

2018 ◽

Vol 14 (7s) ◽

pp. 13-20 ◽

Cited By ~ 2

Author(s):

Maria Isabel Gallegos Sancho ◽

Raúl Márquez-Vázquez ◽

Alfonso Sánchez-Muñoz

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Case Studies ◽

Triple Negative ◽

Metastatic Breast ◽

Breast Cancer Case ◽

Cancer Case

Download Full-text

Orbitotemporal Bone Cyst of Metastatic Breast Cancer: Case Report and Literature Review

World Neurosurgery ◽

10.1016/j.wneu.2019.07.076 ◽

2019 ◽

Vol 130 ◽

pp. 267-270

Author(s):

Yoshifumi Tao ◽

Kenji Yagi ◽

Hirotake Nishimura ◽

Keijirou Hara ◽

Shunji Matsubara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Case Report ◽

Literature Review ◽

Bone Cyst ◽

Metastatic Breast ◽

Breast Cancer Case ◽

Cancer Case

Download Full-text

Massive inflammatory reaction following the removal of a ruptured silicone implant masking the invasive breast cancer – case report and literature review

Polish Journal of Surgery ◽

10.1515/pjs-2016-0026 ◽

2016 ◽

Vol 88 (1) ◽

Author(s):

Piotr Nowaczyk ◽

Aleksandra Budnicka ◽

Mateusz Wichtowski ◽

Paweł Kurzawa ◽

Dawid Murawa

Keyword(s):

Breast Cancer ◽

Histopathological Examination ◽

Breast Implants ◽

Breast Cancer Case ◽

Left Breast ◽

Cancer Case ◽

Axillary Lymph Nodes ◽

Axillary Lymph ◽

Breast Cancers ◽

Inflammatory Infiltration

AbstractThis paper presents a case of a patient with invasive ductal breast cancer following breast augmentation. Following breast implants rupture in March 2013 the breast implants have been removed – histopathological examination revealed leaked silicone with inflammatory infiltration, without evidence of cancerous lesions. Diagnostic imaging revealed multiple encapsulated silicone particles and clusters of post-inflammatory macrocalcifications in both breasts. In January 2014 the patient presented with symptoms of massive inflammation of the left breast. Following surgical consultation the patient had undergone radical left-sided mastectomy with lymphadenectomy. Postoperative histopathological examination revealed a multifocal advanced invasive ductal cancer G3 pT3pN3a (vascular invasion, metastases in 11 of 12 examined axillary lymph nodes). Following surgery the patient was qualified for further treatment – chemotherapy, radiotherapy, hormone therapy. The discussion includes a review of literature on the risk evaluation of co-occurrence of breast cancers in women with silicone breast implants and presents diagnostic challenges of breast cancer in this patient group.

Download Full-text

Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2681-0 ◽

2013 ◽

Vol 141 (2) ◽

pp. 167-172 ◽

Cited By ~ 12

Author(s):

Eleonora Teplinsky ◽

Derrick Cheung ◽

Ilan Weisberg ◽

Ramon E. A. Jacobs ◽

Martin Wolff ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Case Report ◽

Hepatitis B ◽

Metastatic Breast ◽

Breast Cancer Case ◽

Cancer Case ◽

Review Of Literature ◽

Hepatitis B Reactivation

Download Full-text

Solitary metastatic breast carcinoma in a trigeminal nerve mimicking a trigeminal neurinoma

Journal of Neurosurgery ◽

10.3171/jns.1996.85.4.0677 ◽

1996 ◽

Vol 85 (4) ◽

pp. 677-680 ◽

Cited By ~ 5

Author(s):

Ichiro Nakano ◽

Koichi Iwasaki ◽

Akinori Kondo

Keyword(s):

Breast Cancer ◽

Trigeminal Nerve ◽

Unusual Case ◽

Metastatic Breast ◽

Metastatic Tumor ◽

Content Type ◽

Metastatic Breast Carcinoma ◽

Trigeminal Neurinoma ◽

History Of ◽

Histopathological Studies

✓ An unusual case of a metastatic adenocarcinoma located entirely within the trigeminal nerve is reported. The patient, with a history of breast cancer, presented with a pure trigeminal mononeuropathy. The neurological and neuroradiological findings in this patient were quite similar to those of a patient with trigeminal neurinoma. Surgery revealed that the tumor was located within the trigeminal nerve and its appearance was similar to that of a neurinoma. However, histopathological studies proved the tumor to be an adenocarcinoma that was related to the breast cancer treated earlier. A solitary metastatic tumor arising solely in a trigeminal nerve is quite rare; this is the first report of such a case metastasized from breast cancer.

Download Full-text

Subtrochanteric Fracture as First Sign of Metastatic Breast Cancer: Case Presentation

Journal of Medical Cases ◽

10.14740/jmc2216w ◽

2015 ◽

Vol 6 (8) ◽

pp. 367-372

Author(s):

Bogdan Deleanu ◽

Radu Prejbeanu ◽

Dan Crisan ◽

Dinu Vermesan ◽

Vlad Predescu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Breast Cancer Case ◽

Subtrochanteric Fracture ◽

Cancer Case ◽

Case Presentation

Download Full-text

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature

Frontiers in Oncology ◽

10.3389/fonc.2021.651723 ◽

2021 ◽

Vol 11 ◽

Author(s):

Giovanna Garufi ◽

Luisa Carbognin ◽

Armando Orlandi ◽

Antonella Palazzo ◽

Giampaolo Tortora ◽

...

Keyword(s):

Breast Cancer ◽

Bone Marrow ◽

Clinical Trials ◽

Scientific Evidence ◽

Case Series ◽

Metastatic Breast ◽

Signs And Symptoms ◽

Breast Cancer Case ◽

Clinical History ◽

Cancer Case

The efficacy and safety of the combination of endocrine therapy (ET) and CDK4/6 inhibitors for patients with hormone receptor (HR)-positive HER2-negative metastatic breast cancer (BC) presenting with visceral crisis or life-threatening conditions represent a challenge for daily clinical practice. Indeed, the peculiarity of this clinical presentation (signs and symptoms of rapidly progressive disease) does not allow to include such patients in a trial aiming for drug approval. On the basis of the scientific evidence available so far, chemotherapy represents the standard of care according to guidelines, on the basis of the more rapid activity in comparison with ET alone. Besides, the combination of ET and CDK4/6 inhibitors have demonstrated in clinical trials to have clinically impactful activity in a short time, thus suggesting a potential role in advanced tumors that require rapid response. Herein, we report the clinical history of a young woman with HR-positive HER2-negative metastatic BC and a pancytopenia due to carcinomatosis of the bone marrow receiving letrozole and leuprorelin plus the CDK4/6 inhibitor palbociclib, who significantly derived clinical benefit from treatment. Considering that these peculiar cases are excluded from clinical trials, the estimation of the magnitude of the benefit of the newer ET combination may potentially represent a practical question for large case series and real-world studies.

Download Full-text